# Personal Patient Profile - Prostate (P3P): Applying what matters most

Donna L. Berry, PhD, RN University of Washington MASCC 2019

# Localized Prostate Cancer: The Ultimate Treatment Decision

- Today, versus 20 years ago, we know a bit more to say when our patients ask, "but doctor, which treatment works the best?"
- We still reply with many "ifs" and "caveats."



# Treatment Decision Making in Men with Prostate Cancer

R29 CA 77372 1998-2003


Qualitative: Patients

Qualitative: MD's

Quantitative

Pilot Intervention

#### The Decision Process – Individual Interviews



### Qualitative Results

- Core decision-making process: "Making the best choice for someone like me"
- Men are compelled to place the diagnosis and all the potential outcomes in the context of their own lives.
  - What prostate cancer or other cancer has meant to them in the past
  - 'Who I am' and 'what I do' determines perspective
  - Guidance sought from others who have some similar contexts
  - Force MD to step into their contexts with the question, 'what would you do if you were me?'

### Conclusions

- Overall, this mixed methods study suggested that accurate information communicated to patients is of primary importance, not only for satisfaction with decision making but also for the actual treatment choice.
- Patient-reported factors are at play in the treatment decision and associated outcomes
  - Self- appraisal/personal priorities
  - Anxiety
  - Intimate relationships
  - Shared decision control (MD influence)
  - Use of the Internet

#### **Decisional Needs**

### High Quality Decision





Figure 1. Adapted Ottawa Decision Support Framework




- How could we facilitate the patient-report of personal factors and also educate on medical factors tailored to men's priorities?
- Could we make available any time, anywhere as preparation for decision making?

# "Let me tell you what you need to know"



# "Let me set you up with some information"



### P3P: What it is and what it does

- Interactive Web-based decision support system in English and Spanish that works on all devices
- Synthesizes medical facts with patient factors (beliefs, preferences, concerns)
- Multi-media education and coaching based on patient priorities
- Prepares a man for the options consultation with the clinician and decision

## Landing page



P3P is for





#### Clinicians

share their values, preferences, and choices




















## Components of the Intervention

- Taking part in the treatment decision
  - Driven by Decisional Control Scale
- Understanding statistics-text and graphic
  - Driven by most influential outcome
- Top information topics text/print-out
  - Driven by Information Priorities



l of 1 11/26/2013 3:15 PM

## Components of the Intervention

- Influential people: text and video
  - Driven by most influential person
- Influential outcomes: text and video
  - Driven by most influential outcomes
- Current symptoms: text and video
  - Driven by EPIC
- Other informational web sites: text and printout

## P3P RCT I (2007-2011)



UROLOGIC ONCOLOGY

Urologic Oncology: Seminars and Original Investigations 31 (2013) 1012-1021

Original article

The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: A multi-center randomized trial

Donna L. Berry, Ph.D., R.N., F.A.A.N.<sup>a</sup>, Barbara Halpenny, M.A.<sup>a</sup>, Fangxin Hong, Ph.D.<sup>a,b</sup>, Seth Wolpin, M.P.H., Ph.D., R.N.<sup>c</sup>, William B. Lober, M.D.<sup>d</sup>, Kenneth J. Russell, M.D.<sup>e</sup>, William J. Ellis, M.D.<sup>f</sup>, Usha Govindarajulu, Ph.D.<sup>g</sup>, Jaclyn Bosco, Ph.D.<sup>a</sup>, B. Joyce Davison, Ph.D., R.N.<sup>h</sup>, Gerald Bennett, Ph.D., A.P.R.N., F.A.A.N.<sup>i</sup>, Martha K. Terris, M.D.<sup>j</sup>, Andrea Barsevick, Ph.D., R.N., F.A.A.N.<sup>k</sup>, Daniel W. Lin, M.D.<sup>f,1</sup>, Claire C. Yang, M.D.<sup>f,1</sup>, Greg Swanson, M.D.<sup>m.\*</sup>

Results: A total of 494 eligible men were randomized (266 intervention; 228 control). The intervention reduced adjusted decisional conflict over time compared with the control group, for the uncertainty score (estimate –3.61; (confidence interval, –7.01, 0.22), and values clarity (estimate –3.57; confidence interval (–5.85,–1.30). Borderline effect was seen for the total decisional conflict score (estimate –1.75; confidence interval (–3.61,0.11). Time-to-treatment was comparable between groups, while undecided men in the intervention group chose brachytherapy more often than in the control group. Acceptability and usefulness were highly rated.

### Competitive renewal

- Hybrid Type 1 effectivenessimplementation trial
  - A study in which a clinical intervention is tested while gathering information delivery and implementation in a real-world environment.
  - P3P met suggested criteria
    - low-risk intervention with face validity
    - evidence of efficacy in a different, but related, population.

My Home

My Top Concerns

**Statistics** 

My Decision Role

**More About Prostate Cancer** 

What Do You Think?

Click to see other topics:

#### Outcomes

✓ Years I Expect to Live

✓ Bladder Function

Sexual Function

✓ Bowel Function

#### Lifestyle

✓ Work or Occupation Activities

✓ Recreational Activities

#### People

✓ Spouse/Partner

✓ Co-worker

✓ Friend

✓ Family Member

#### Current Symptoms

✓ Bladder

✓ Sexual

✓ Bowel

#### My Top Concerns

Based on your answers, we've calculated which factors are most important to you. Start with the one below and use the links on the left to explore other areas.

#### Years I Expect to Live

Based on your answers, how long you expect to live (this is also called survival) is important to you as you decide on your prostate cancer care.

#### Age and other things that affect survival

Nearly all men with localized prostate cancer ② will live at least 10 years after their diagnosis ③. They may die sooner for another reason, like accidents or other illnesses. In general, prostate cancer is a slow-growing cancer.

For men with a low risk ② of cancer spreading or returning, there is no proof that any one kind of care will help them live longer than another kind of care. For men with a medium-to high-risk ③ cancer, studies show that removing or treating the cancer is better than only watching it.

The most important thing in the risk of your cancer growing or spreading is the Gleason score of your cancer. There is good research that says that this score will predict how soon a man's cancer will spread and how many years he will live. Your doctor will talk to you about your Gleason Score and risk of your cancer spreading or returning.

The way you feel about your own age now and how long you expect to live is important in choosing your prostate cancer care. Other diseases or illnesses you have, or that your family has, also can affect how long you expect to live.

#### TALK TO YOUR DOCTOR

Talk to your doctor about your age and how long you expect to live. For example, you might say:

"Doctor I feel like a young man at (say your age) and like I've





Somewhat

Satisfaction

Donna Berry Patient Report Date: 2016-06-22 DOB: 1976-06-25 (40 yo) Influential Personal Factors Option Preference Current decision status on options: Bladder Function A lot Rec. Activities Little A lot Little I haven't started to think about the options, Sexual Function Family Member but I want to start Some Work Activities None Years | Expect to Live Decision Control Preference Some Friend None Co-worker None **Bowel Function** Spouse/Partner I prefer that my doctor(s) and I share the decision about which option is best." Expanded Prostate Cancer Index Composite Short Form (Past 4 weeks) Higher scores indicate better QOL 0 ← Worse Better - 100 Better → 100 0 ← Worse 0 -- Worse Better → 18 Urinary Incontinen Bowel Vitality/Hormonal Urinary Irritation Sexual **FPIC Domains** Sexual Urinary Incontinence More than once a week Erectile ability Frequency Very Poor to None Dribbling Frequent dribbling Orgasm ability Very Poor to None Pad use 2 pads per day Erections quality None at all Leaking Big Problem Erections when I Never want Urinary Irritation/Obstruction Overall sexual Very good ability Pain/burning No problem Bleeding No problem Overall sexual Very small problem problem Stream Small Problem Frequency Big Problem Vitality/Hormonal Hot flashes No problem Bowel Breasts Big Problem Urgency No problem tender/larger Frequency No problem Feeling depressed No problem Control No problem Energy No problem Blood No problem Weight change Big Problem Abd/pelvic/rectal No problem pain Overall bowel No problem Sexual Interest, Activity and Satisfaction (Past 4 weeks) Interest level Quite a bit Use of erectile aids 4 or more times Activity level 4 or more times Erectile aids:


Pills, Penile Injection, Vacuum Erection Device, Other: Fancy machine

### RCT-2013 to 2016


- Sites in Boston, MA, Atlanta, GA, Charlottesville, VA & southern California.
- 392 men were randomized (198 intervention; 194 usual care) and 305 men returned 1-month outcomes (152;153).
  - Diverse sample with regard to race, income and education
- The adjusted, multivariable model revealed significantly reduced conflict in the intervention group (-5.00 [-9.40, -0.59]).
- Other predictors of conflict included income, marital/partner status, decision status, number of consults, clinical site and D'Amico risk classification.

Berry et al., 2018

# Patient-reported influential factors: Pooled responses from both RCTs



## Odds of endorsing a factor



## Summary

- In a preference-sensitive decision scenario, an assessment of patientreported priorities provides opportunity for tailored intervention.
- A tailored intervention reduces patientreported conflict associated with the decision.
- Personal priorities vary based on race/ethnicity in the US, further underscoring the need for customization.

## Co-Investigators and Team

- University of Washington
  - William J Ellis, MD, Dept of Urology
  - Claire Yang, MD, Dept of Urology
  - Daniel W Lin, MD, Dept of Urology
  - Kenneth J Russell, MD, Radiation Oncology
  - Seth Wolpin, PhD, RN, Biobehavioral Nursing and Health (Systems) Informatics
  - William B Lober, MD, Biobehavioral Nursing and Health (Systems) Informatics
  - Justin McReynolds, MS, Biobehavioral Nursing and Health (Systems) Informatics
- P3P I Site Investigators
  - B. Joyce Davison, PhD, RN, Prostate Centre, BC,
  - Andrea Barsevick, PhD, RN, AOCN, Fox Chase Cancer Center
  - Gerald Bennett, PhD, RN, Medical College of Georgia
  - Greg Swanson, MD, University of Texas Health Sciences Center at San Antonio
- P3P II Site Investigators
  - Martin Sanda, MD
  - Vraj Master, MD
  - Gary Chien, MD, Southern CA Kaiser Permanente
  - Tracy Krupski, MD, University of Virginia, Dept of Urology
  - Peter Chang, MD, Beth Israel Deaconess, Dept of Urology
- Dana-Farber Cancer Institute
  - Barbara Halpenny, MA
  - Fangxin Hong, PhD
  - Julia Whitmore, MD